Published in Neoplasia on December 01, 2007
Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. Cancer Res (2009) 2.93
Notch-1 induces epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells. Cancer Lett (2011) 2.24
Emerging role of Notch in stem cells and cancer. Cancer Lett (2008) 1.88
Radiation resistance of cancer stem cells: the 4 R's of radiobiology revisited. Stem Cells (2010) 1.78
Targeting Notch signaling pathway to overcome drug resistance for cancer therapy. Biochim Biophys Acta (2010) 1.59
Role of Notch and its oncogenic signaling crosstalk in breast cancer. Biochim Biophys Acta (2010) 1.50
Sca-1 identifies the tumor-initiating cells in mammary tumors of BALB-neuT transgenic mice. Neoplasia (2008) 1.07
Erythropoietin receptor response circuits. Curr Opin Hematol (2010) 1.07
Notch1 is required for hypoxia-induced proliferation, invasion and chemoresistance of T-cell acute lymphoblastic leukemia cells. J Hematol Oncol (2013) 1.05
Are cancer stem cells radioresistant? Future Oncol (2010) 1.01
Association between pharmaceutical support and basic science research on erythropoiesis-stimulating agents. Arch Intern Med (2010) 0.99
Notch signaling proteins: legitimate targets for cancer therapy. Curr Protein Pept Sci (2010) 0.98
Erythropoietin promotes breast tumorigenesis through tumor-initiating cell self-renewal. J Clin Invest (2014) 0.94
Down-regulation of the fetal stem cell factor SOX17 by H33342: a mechanism responsible for differential gene expression in breast cancer side population cells. J Biol Chem (2009) 0.93
Evaluating erythropoietin-associated tumor progression using archival tissues from a phase III clinical trial. Stem Cells (2009) 0.93
Radiation-induced Notch signaling in breast cancer stem cells. Int J Radiat Oncol Biol Phys (2013) 0.91
RNA interference-mediated inhibition of erythropoietin receptor expression suppresses tumor growth and invasiveness in A2780 human ovarian carcinoma cells. Am J Pathol (2009) 0.89
Layered signaling regulatory networks analysis of gene expression involved in malignant tumorigenesis of non-resolving ulcerative colitis via integration of cross-study microarray profiles. PLoS One (2013) 0.80
Autocrine/paracrine erythropoietin regulates migration and invasion potential and the stemness of human breast cancer cells. Cancer Biol Ther (2013) 0.80
1 RBC Concentrates. Transfus Med Hemother (2009) 0.79
Prognostic significance of erythropoietin in pancreatic adenocarcinoma. PLoS One (2011) 0.78
Association between FBP1 and hypoxia-related gene expression in clear cell renal cell carcinoma. Oncol Lett (2016) 0.77
NOTCH1 is a poor prognostic factor for breast cancer and is associated with breast cancer stem cells. Onco Targets Ther (2016) 0.76
Combination therapy of RY10-4 with the γ-secretase inhibitor DAPT shows promise in treating HER2-amplified breast cancer. Oncotarget (2016) 0.76
Neoplasia: the second decade. Neoplasia (2008) 0.75
Targeting the Notch signaling pathway in cancer therapeutics. Thorac Cancer (2014) 0.75
The War on Cancer rages on. Neoplasia (2009) 0.75
Anaemia: a rare but neglected problem among Finnish patients receiving chemotherapy for solid tumours. Support Care Cancer (2010) 0.75
Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A (2003) 59.17
Stem cells, cancer, and cancer stem cells. Nature (2001) 50.27
Identification of human brain tumour initiating cells. Nature (2004) 38.87
In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev (2003) 20.77
Identification of pancreatic cancer stem cells. Cancer Res (2007) 18.36
Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res (2005) 13.89
Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci U S A (2007) 11.94
Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res (2005) 11.52
Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet (2003) 11.47
The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst (2006) 10.06
A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res (2005) 7.86
CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res (2006) 6.35
Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells. Breast Cancer Res (2004) 5.60
Do erythropoietin receptors on cancer cells explain unexpected clinical findings? J Clin Oncol (2006) 5.56
Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin Cancer Res (2006) 5.21
WNT/beta-catenin mediates radiation resistance of mouse mammary progenitor cells. Proc Natl Acad Sci U S A (2007) 4.97
Relevance of breast cancer cell lines as models for breast tumours: an update. Breast Cancer Res Treat (2004) 4.89
Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol (2005) 4.82
Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol (2007) 3.12
Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol (2003) 2.53
Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease. Neurology (2006) 2.21
Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev (2006) 2.06
Wnt/beta-catenin mediates radiation resistance of Sca1+ progenitors in an immortalized mammary gland cell line. J Cell Sci (2007) 1.98
Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res (2001) 1.74
Rel/NF-kappaB can trigger the Notch signaling pathway by inducing the expression of Jagged1, a ligand for Notch receptors. EMBO J (1999) 1.61
Erythropoietin regulates tumour growth of human malignancies. Carcinogenesis (2003) 1.54
Notch-independent regulation of Hes-1 expression by c-Jun N-terminal kinase signaling in human endothelial cells. Lab Invest (2006) 1.24
Immunohistochemical expression of erythropoietin and erythropoietin receptor in breast carcinoma. Cancer (2002) 1.14
Inhibition of erythropoietin signalling destroys xenografts of ovarian and uterine cancers in nude mice. Br J Cancer (2001) 1.09
Activation of the transcription factor NF-kappaB by the erythropoietin receptor: structural requirements and biological significance. Cell Signal (2001) 1.08
Acute neuroprotective synergy of erythropoietin and insulin-like growth factor I. Proc Natl Acad Sci U S A (2004) 1.08
Erythropoietin receptor expression in non-small cell lung carcinoma: a question of antibody specificity. Stem Cells (2006) 1.05
Anemia is associated with lower local-regional control and survival after radiation therapy for head and neck cancer: a prospective study. Radiology (1996) 1.03
Erythropoietin induces cancer cell resistance to ionizing radiation and to cisplatin. Mol Cancer Ther (2004) 1.02
Erythropoietin as an angiogenic factor in gastric carcinoma. Histopathology (2003) 1.00
Pretreatment hemoglobin level influences local control and survival of T1-T2 squamous cell carcinomas of the glottic larynx. J Clin Oncol (1995) 0.99
Erythropoietin and G-CSF receptors in human tumor cells: expression and aspects regarding functionality. Tumori (2002) 0.98
Erythropoietin restores the anemia-induced reduction in radiosensitivity of experimental human tumors in nude mice. Int J Radiat Oncol Biol Phys (2003) 0.97
Anemia is associated with decreased survival and increased locoregional failure in patients with locally advanced head and neck carcinoma: a secondary analysis of RTOG 85-27. Int J Radiat Oncol Biol Phys (1998) 0.96
Chemosensitization by erythropoietin through inhibition of the NF-kappaB rescue pathway. Oncogene (2005) 0.95
Erythropoietin receptor expression in human melanoma cells. Melanoma Res (2000) 0.93
Induction of signalling in non-erythroid cells by pharmacological levels of erythropoietin. Neurodegener Dis (2006) 0.90
Enhanced radiosensitivity in experimental tumours following erythropoietin treatment of chemotherapy-induced anaemia. Br J Cancer (1998) 0.89
The impact of blood hemoglobin content on the outcome of radiotherapy. The Freiburg experience. Strahlenther Onkol (1998) 0.89
The erythropoietin-receptor pathway modulates survival of cancer cells. Oncogene (2004) 0.86
Blood hemoglobin level and treatment outcome of early breast cancer. Strahlenther Onkol (2004) 0.86
The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst (2006) 10.06
Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci U S A (2010) 5.59
Do erythropoietin receptors on cancer cells explain unexpected clinical findings? J Clin Oncol (2006) 5.56
The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med (2008) 5.01
Actin up: regulation of podocyte structure and function by components of the actin cytoskeleton. Trends Cell Biol (2007) 4.31
Effects of radiation on normal tissue: consequences and mechanisms. Lancet Oncol (2003) 3.70
Synaptopodin orchestrates actin organization and cell motility via regulation of RhoA signalling. Nat Cell Biol (2006) 3.31
Animal models for medical countermeasures to radiation exposure. Radiat Res (2010) 2.83
In vivo imaging, tracking, and targeting of cancer stem cells. J Natl Cancer Inst (2009) 2.39
Synaptopodin regulates the actin-bundling activity of alpha-actinin in an isoform-specific manner. J Clin Invest (2005) 2.39
Models for evaluating agents intended for the prophylaxis, mitigation and treatment of radiation injuries. Report of an NCI Workshop, December 3-4, 2003. Radiat Res (2004) 2.33
Combining radiotherapy and immunotherapy: a revived partnership. Int J Radiat Oncol Biol Phys (2005) 2.29
Metabolic state of glioma stem cells and nontumorigenic cells. Proc Natl Acad Sci U S A (2011) 2.13
Synaptopodin protects against proteinuria by disrupting Cdc42:IRSp53:Mena signaling complexes in kidney podocytes. Am J Pathol (2007) 2.13
A sense of danger from radiation. Radiat Res (2004) 2.02
Radiation-induced reprogramming of breast cancer cells. Stem Cells (2012) 1.83
Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin Cancer Res (2003) 1.83
Molecular response to cetuximab and efficacy of preoperative cetuximab-based chemoradiation in rectal cancer. J Clin Oncol (2009) 1.82
Radiation resistance of cancer stem cells: the 4 R's of radiobiology revisited. Stem Cells (2010) 1.78
The biological effectiveness of antiproton irradiation. Radiother Oncol (2006) 1.66
T-cell responses to survivin in cancer patients undergoing radiation therapy. Clin Cancer Res (2008) 1.61
Maximizing tumor immunity with fractionated radiation. Int J Radiat Oncol Biol Phys (2011) 1.60
Survival and self-renewing capacity of breast cancer initiating cells during fractionated radiation treatment. Breast Cancer Res (2010) 1.59
The combination of ionizing radiation and peripheral vaccination produces long-term survival of mice bearing established invasive GL261 gliomas. Clin Cancer Res (2006) 1.51
A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides. Clin Cancer Res (2006) 1.48
Safety and efficacy of hyperbaric oxygen therapy for the treatment of interstitial cystitis: a randomized, sham controlled, double-blind trial. J Urol (2006) 1.47
Capsaicin, a component of red peppers, inhibits the growth of androgen-independent, p53 mutant prostate cancer cells. Cancer Res (2006) 1.45
Ionizing radiation affects human MART-1 melanoma antigen processing and presentation by dendritic cells. J Immunol (2004) 1.44
National Institutes of Health funding in radiation oncology: a snapshot. Int J Radiat Oncol Biol Phys (2013) 1.42
Role of dendritic cell phenotype, determinant spreading, and negative costimulatory blockade in dendritic cell-based melanoma immunotherapy. J Immunother (2004) 1.40
Molecular mechanisms of late normal tissue injury. Semin Radiat Oncol (2007) 1.40
Radiation enhances regulatory T cell representation. Int J Radiat Oncol Biol Phys (2010) 1.39
Ionizing radiation activates the Nrf2 antioxidant response. Cancer Res (2010) 1.35
The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIV-associated human cancer cells. Cancer Res (2002) 1.31
Cytokines in radiobiological responses: a review. Radiat Res (2012) 1.29
Macrophages from irradiated tumors express higher levels of iNOS, arginase-I and COX-2, and promote tumor growth. Int J Radiat Oncol Biol Phys (2007) 1.28
After the bomb drops: a new look at radiation-induced multiple organ dysfunction syndrome (MODS). Int J Radiat Biol (2011) 1.24
T-cell responses to HLA-A*0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer. Clin Cancer Res (2003) 1.24
Links between innate immunity and normal tissue radiobiology. Radiat Res (2010) 1.19
Irradiation of the potential cancer stem cell niches in the adult brain improves progression-free survival of patients with malignant glioma. BMC Cancer (2010) 1.19
Radiotherapy decreases vascular density and causes hypoxia with macrophage aggregation in TRAMP-C1 prostate tumors. Clin Cancer Res (2009) 1.19
Nuclear relocation of the nephrin and CD2AP-binding protein dendrin promotes apoptosis of podocytes. Proc Natl Acad Sci U S A (2007) 1.16
Hypoxia in human colorectal adenocarcinoma: comparison between extrinsic and potential intrinsic hypoxia markers. Int J Radiat Oncol Biol Phys (2006) 1.12
Compartmental responses after thoracic irradiation of mice: strain differences. Int J Radiat Oncol Biol Phys (2005) 1.11
Radiation responses of cancer stem cells. J Cell Biochem (2009) 1.08
Anthracyclines, proteasome activity and multi-drug-resistance. BMC Cancer (2005) 1.08
The confluence of stereotactic ablative radiotherapy and tumor immunology. Clin Dev Immunol (2011) 1.05
Folate-targeted immunotherapy effectively treats established adjuvant and collagen-induced arthritis. Arthritis Res Ther (2006) 1.05
Human dendritic cell maturation by adenovirus transduction enhances tumor antigen-specific T-cell responses. J Immunother (2004) 1.03
The role of the ubiquitin/proteasome system in cellular responses to radiation. Oncogene (2003) 1.03
Prostratin and bortezomib are novel inducers of latent Kaposi's sarcoma-associated herpesvirus. Antivir Ther (2005) 1.02
High-throughput screening identifies two classes of antibiotics as radioprotectors: tetracyclines and fluoroquinolones. Clin Cancer Res (2009) 1.02
N-acetyl-L-cysteine inhibits 26S proteasome function: implications for effects on NF-kappaB activation. Free Radic Biol Med (2002) 1.01
Bronchoalveolar lavage and interstitial cells have different roles in radiation-induced lung injury. Int J Radiat Biol (2003) 1.00
Novel streptavidin-functionalized silicon nanowire arrays for CD4+ T lymphocyte separation. Nano Lett (2010) 1.00
Metabolic differences in breast cancer stem cells and differentiated progeny. Breast Cancer Res Treat (2014) 0.98
SOCS3 regulates p21 expression and cell cycle arrest in response to DNA damage. Cell Signal (2008) 0.98
Regulatory T cells in radiotherapeutic responses. Front Oncol (2012) 0.98
Preparing for the future of radiation oncology. J Am Coll Radiol (2007) 0.97
The proteasome inhibitor MG-132 sensitizes PC-3 prostate cancer cells to ionizing radiation by a DNA-PK-independent mechanism. BMC Cancer (2005) 0.97
Hyperthermia-induced proteasome inhibition and loss of androgen receptor expression in human prostate cancer cells. Cancer Res (2005) 0.96
Spinal cord tolerance to single-fraction partial-volume irradiation: a swine model. Int J Radiat Oncol Biol Phys (2010) 0.96
Functional phenotype of macrophages depends on assay procedures. Int Immunol (2007) 0.95
The RNA-binding protein Musashi-1 regulates proteasome subunit expression in breast cancer- and glioma-initiating cells. Stem Cells (2014) 0.95
Immunosensitization of tumor cells to dendritic cell-activated immune responses with the proteasome inhibitor bortezomib (PS-341, Velcade). J Immunol (2006) 0.95
TIMAP, a novel CAAX box protein regulated by TGF-beta1 and expressed in endothelial cells. Am J Physiol Cell Physiol (2002) 0.95
Anti-inflammatory function of arctiin by inhibiting COX-2 expression via NF-κB pathways. J Inflamm (Lond) (2011) 0.94
Lymphatic fistulas: obliteration by low-dose radiotherapy. Strahlenther Onkol (2005) 0.94
Radioprotective effects of Bmi-1 involve epigenetic silencing of oxidase genes and enhanced DNA repair in normal human keratinocytes. J Invest Dermatol (2011) 0.93
Ex vivo expansion of highly cytotoxic human NK cells by cocultivation with irradiated tumor cells for adoptive immunotherapy. Cancer Res (2013) 0.93
Differential expression of immune-associated cancer regulatory genes in low- versus high-dose-rate irradiated AKR/J mice. Genomics (2011) 0.92
Oxygen levels do not determine radiation survival of breast cancer stem cells. PLoS One (2012) 0.92
Induction of radioprotective peroxiredoxin-I by ionizing irradiation. J Neurosci Res (2002) 0.92
Tumor cells with low proteasome subunit expression predict overall survival in head and neck cancer patients. BMC Cancer (2014) 0.91
Neu-induced retroviral rat mammary carcinogenesis: a novel chemoprevention model for both hormonally responsive and nonresponsive mammary carcinomas. Cancer Res (2006) 0.91
Radiation-induced Notch signaling in breast cancer stem cells. Int J Radiat Oncol Biol Phys (2013) 0.91
The effects of tea extracts on proinflammatory signaling. BMC Med (2006) 0.91
HDJ-2 as a target for radiosensitization of glioblastoma multiforme cells by the farnesyltransferase inhibitor R115777 and the role of the p53/p21 pathway. Cancer Res (2006) 0.91
Protection against radiation-induced bone marrow and intestinal injuries by Cordyceps sinensis, a Chinese herbal medicine. Radiat Res (2006) 0.91
Enhanced tumor responses to dendritic cells in the absence of CD8-positive cells. J Immunol (2004) 0.91
Immunomagnetic diffractometry for detection of diagnostic serum markers. J Am Chem Soc (2007) 0.90
High throughput screening of small molecule libraries for modifiers of radiation responses. Int J Radiat Biol (2011) 0.90
Alteration of cytokine profiles in mice exposed to chronic low-dose ionizing radiation. Biochem Biophys Res Commun (2010) 0.89
NF-kappa B, cytokines, proteasomes, and low-dose radiation exposure. Mil Med (2002) 0.89
Spinal cord tolerance to reirradiation with single-fraction radiosurgery: a swine model. Int J Radiat Oncol Biol Phys (2011) 0.89
Differential Effects of the Proteasome Inhibitor NPI-0052 against Glioma Cells. Transl Oncol (2010) 0.88